Trial Profile
A retrospective study to evaluate the safety and efficacy of tolvaptan during a 6-month follow-up in acute decompensated heart failure (ADHF) patients with severe chronic kidney disease (CKD)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Apr 2017
Price :
$35
*
At a glance
- Drugs Tolvaptan (Primary) ; Loop diuretics
- Indications Heart failure; Renal failure
- Focus Adverse reactions; Therapeutic Use
- 26 Apr 2017 Status changed from not stated to completed.
- 26 Apr 2017 New trial record